Optimizing Ribavirin Exposure by Therapeutic Drug Monitoring Improves Treatment Response in Patients With Chronic Hepatitis C Genotype 1

Optimum Ribavirin Exposure Overcomes Racial Disparity in Efficacy of Peginterferon and Ribavirin Treatment for Hepatitis C Genotype 1

(2012) Runyan Jin et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Clinical utility of interleukin-28B testing in patients with genotype 1

(2012) Michelle Lai et al.   HEPATOLOGY

101 SVR4 AND SVR12 WITH AN INTERFERON-FREE REGIMEN OF BI201335 AND BI207127, +/- RIBAVIRIN, IN TREATMENT-NAIVE PATIENTS WITH CHRONIC GENOTYPE-1 HCV INFECTION: INTERIM RESULTS OF SOUND-C2

(2012) S. Zeuzem et al.   JOURNAL OF HEPATOLOGY

Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care

(2012) Brian L Pearlman   LANCET INFECTIOUS DISEASES

Protease inhibitor-based triple therapy in chronic hepatitis C: guidelines by the French Association for the Study of the Liver

(2012) Vincent Leroy et al.   LIVER INTERNATIONAL

Critical review of the use of erythropoietin in the treatment of anaemia during therapy for chronic hepatitis C

(2011) F. Stickel et al.   JOURNAL OF VIRAL HEPATITIS

Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection

(2009) Christophe Hézode et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C

(2008) Véronique Loustaud-Ratti et al.   HEPATOLOGY